Better efficacy than topiramate! Novartis/Amgen Aimovig head-to-head Phase 4 clinical results announced

Novartis and Amgen recently announced that the first phase IV, randomized, double-blind, double-dummy, head-to-head study HER-MES (NCT03828539) to evaluate the migraine drug Aimovig (erenumab) has been published in The medical journal "Cephalalgia"

The HER-MES study was conducted in 777 adult patients with episodic migraine (EM) or chronic migraine (CM) who have not previously received, or are unsuitable, or have received up to 3 preventive migraine therapies that have failed.

The results show that compared with topiramate, Aimovig has higher tolerance and efficacy in preventing migraine

Aimovig is the world's first migraine drug that targets the calcitonin-related gene peptide (CGRP) target and is jointly commercialized by Novartis and Amgen in the United States

Calcitonin-related gene peptide (CGRP) is a neuropeptide that has been shown to be released during migraine attacks and is considered to be the cause of migraine attacks

Up to now, 4 monoclonal antibody migraine therapies targeting CGRP and its receptors have been on the market, namely: Amgen/Novartis Aimovig, Teva Ajovy, Eli Lilly Emgality, and Vyepti (eptinezumab)

Other pharmaceutical companies are developing oral CGRP receptor antagonists

Note: The original text has been deleted

Original source: Novartis announces new publication in Cephalalgia of data showcasing superior tolerability and efficacy of Aimovig® (erenumab) compared with topiramate in migraine prevention